KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide.

Duvuru Geetha, Thomas Neumann, Alexandre Karras, Maria C Cid, Peter A Merkel, Sarah Bray, Alana M Bozeman, David R W Jayne, Members of the ADVOCATE Study Group

RMD Open 11(4) e005743

PMID41052893
PMCIDPMC12506455
DOI10.1136/rmdopen-2025-005743
发表日期2025-10-06
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

BACKGROUND: This study evaluated the efficacy and safety of avacopan versus a prednisone taper in the subgroup of patients with antineutrophil cytoplasmic antibody-associated vasculitis (granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)) receiving cyclophosphamide (CYC) followed by azathioprine (or mycophenolate mofetil) in the ADVOCATE trial. METHODS: Key efficacy outcomes were remission at week 26 and sustained remission at week 52. Additional outcomes included glucocorticoid toxicity, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR) and safety. RESULTS: Of 330 patients receiving study medication, 116 (35.2%) received CYC (avacopan group, n=59; prednisone taper group, n=57). Remission at week 26 and sustained remission at week 52 were achieved by 37/59 (62.7%) and 33/59 (55.9%) patients in the avacopan group and 34/57 (59.6%) and 30/57 (52.6%) in the prednisone taper group, respectively. Over 52 weeks, relapses were observed in 13.0% in the avacopan group and 22.6% in the prednisone taper group. Improvement in eGFR, speed of albuminuria reduction and differences in glucocorticoid toxicity favoured the avacopan group. Serious adverse events occurred in 55.9% and 56.1% of patients in the avacopan and prednisone taper groups, respectively. CONCLUSIONS: This subgroup analysis of patients who received CYC shows similar rates of remission in the avacopan and prednisone taper groups. Compared with the prednisone taper regimen, the avacopan regimen was associated with a numerically lower relapse rate, greater improvement in eGFR, faster reduction in UACR, lower glucocorticoid-related toxicity and similar overall safety. These results support the use of avacopan in combination with CYC to treat GPA or MPA. TRIAL REGISTRATION NUMBER: NCT02994927.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Change from baseline in eGFR in patients with ( A ) kidney involvement at baseline and ( B ) kidney involvement and an eGFR <30 mL/min/1.73 m 2 at baseline. LS mean and SEM are from mixed-effects models for repeated measures with treatment group, visit and treatment-by-visit interaction as factors and baseline as a covariate. CYC, cyclophosphamide; eGFR, estimated glomerular filtration rate; LS, least squares.
非 KM Figure
Figure 2Figure 2. Percentage change from baseline in UACR in patients with albuminuria (≥10 mg/g creatinine) at baseline. Geometric means are from mixed-effects models for repeated measures with the treatment group, visit and treatment-by-visit interaction as factors and baseline as a covariate. Logarithmic transformations were applied to the data before fitting the model. Percent changes from baseline are based on ratios of geometric means of visit over baseline. CYC, cyclophosphamide; LS, least squares; UACR, urinary albumin-to-creatinine ratio.
非 KM Figure